REVEAL AF STUDY
ESTABLISHING NEW STRATEGIES IN AF DETECTION

For Patients at High Risk for AF and Stroke

Visit **medtronic.com/RevealAF** for full details on the study results.



- Prospective, global, multicenter study
- 385 patients received a Reveal™ ICM
- Followed for an average of 22.5 ± 7.7 months

40%

AF detection rate at 30 months.[1]

84.5%

of patients with AF would have been missed if only monitored for 30 days.[1]

DETECTION RATE OF PATIENTS WITH AF OF ≥ 6 MINUTES IN DURATION[1]



Reveal LINQ™
Insertable Cardiac Monitoring System

Medtronic
Further, Together

REVEAL AF STUDY
SECONDARY END POINTS

IN REVEAL AF

AF detected through Reveal™ ICM was found to be actionable by physicians.[1]

56.3%

of patients with AF were prescribed oral anticoagulants during follow-up.[1]

14.8%

of patients with AF were prescribed rhythm-control medication during follow-up.[1]

Reference

[1] Reiffel JA, Verma A, Kowey PR, et al. High Incidence of Previously Unknown ("Silent") Atrial Fibrillation in Patients at High Risk for Atrial Fibrillation and Stroke: Primary Results from the REVEAL AF Study. Abstract presented at Heart Rhythm Society Annual Scientific Sessions. 2017.

Indications, Safety, and Warnings

If you are located in the United States, please refer to the brief statement below to review applicable indications, safety, and warning information. See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 763-514-4000 and/or consult the Medtronic website at medtronic.com.

If you are located outside the United States, see the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.com.

www.medtronic.com/manuals

Consult instructions for use at this website. Manuals can be viewed using a current version of any major Internet browser. For best results, use Adobe Acrobat® Reader with the browser.

Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.

Brief Statement
Reveal LINQ™ LNQ11 Insertable Cardiac Monitor
Indications
The Reveal LINQ insertable cardiac monitor is an implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:

- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
- Patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain, that may suggest a cardiac arrhythmia

This device has not specifically been tested for pediatric use.

Contraindications
There are no known contraindications for the implant of the Reveal LINQ insertable cardiac monitor. However, the patient's particular medical condition may dictate whether or not a subcutaneous, chronically implanted device can be tolerated.

Warnings/Precautions
Patients with the Reveal LINQ insertable cardiac monitor should avoid sources of diathermy, high sources of radiation, electrosurgical cautery, external defibrillation, lithotripsy, therapeutic ultrasound, and radiofrequency ablation to avoid electrical reset of the device, and/or inappropriate sensing as described in the Medical procedure and EMI precautions manual. MRI scans should be performed only in a specified MR environment under specified conditions as described in the Reveal LINQ MRI Technical Manual.

Potential Complications
Potential complications include, but are not limited to, device rejection phenomena (including local tissue reaction), device migration, infection, and erosion through the skin.

See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at medtronic.com.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

Medtronic
710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA

Toll-free in USA: 800.633.8766
Worldwide: +1.763.514.4000

medtronic.com

Medtronic